IMPACT OF BIOIDENTICAL HORMONE THERAPIES: SAFETY AND BENEFITS COMPARED TO CONVENTIONAL THERAPIES
Abstract
Menopause is a physiological process characterized by the permanent cessation of ovarian function, often accompanied by vasomotor symptoms, sleep disturbances, sexual dysfunction, and a significant impact on quality of life. Conventional hormone therapy has been widely used to control these symptoms; however, studies have indicated potential risks associated with certain formulations and routes of administration. In this context, bioidentical hormone therapies (BHT) have gained attention as an alternative therapeutic option. The present study aimed to analyze the impacts of bioidentical hormone therapies compared with conventional hormone therapies, with an emphasis on safety and benefits for menopausal women. This study is an integrative literature review conducted using the PubMed, SciELO, and LILACS databases, including publications from 2015 to 2025. Original articles, systematic reviews, and clinical trials published in Portuguese, English, and Spanish were included. The findings indicate that bioidentical hormone therapies approved by regulatory agencies, particularly transdermal estradiol and micronized progesterone, show similar efficacy to conventional hormone therapy in controlling vasomotor symptoms and may present a more favorable safety profile in certain clinical contexts. However, important limitations were identified regarding compounded formulations, particularly related to standardization, quality control, and evidence of safety. It is concluded that regulated bioidentical hormone therapies may represent an effective option for the management of menopausal symptoms when used in an individualized manner and with appropriate monitoring, whereas compounded preparations should be prescribed with caution.
Author Biography
Nove de Julho University.
References
DONNELLY, L.; BALNEAVES, L. G. Fact or fiction? The role of regulated bodyidentical hormone therapy for menopausal women. Nursing for Women’s Health, v. 26, n. 2, p. 143-151, 2022. DOI: https://doi.org/10.1016/j.nwh.2022.01.012
FILES, J.; KLING, J. M. Transdermal delivery of bioidentical estrogen in
menopausal hormone therapy: a clinical review. Expert Opinion on Drug Delivery, v. 17, n. 9, p. 927-934, 2019. DOI: https://doi.org/10.1080/17425247.2020.1700949
FLORES, V. A.; PAL, L.; MANSON, J. E. Hormone therapy in menopause: concepts, controversies, and approach to treatment. Endocrine Reviews, v. 42, n. 6, p. 720-752, 2021. DOI: https://doi.org/10.1210/endrev/bnab011
GAUDARD, A. M. I. S. et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews, v. 2016, n. 8, CD010407, 2016. DOI: https://doi.org/10.1002/14651858.CD010407.pub2
HILL, D. A.; CRIDER, M.; HILL, S. R. Hormone therapy and other treatments for symptoms of menopause. American Family Physician, v. 94, n. 11, p. 884-889, 2016. Disponível em: https://pubmed.ncbi.nlm.nih.gov/27929271/
HOLTORF, K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgraduate Medicine, v. 121, n. 1, p. 73-85, 2009. DOI: https://doi.org/10.3810/pgm.2009.01.1949
L'HERMITE, M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric, v. 20, n. 4, p. 331338, 2017. DOI: http://dx.doi.org/10.1080/13697137.2017.1291607
L'HERMITE, M. Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use. Climacteric, 2017. DOI: https://doi.org/10.1080/13697137.2017.1285277
LIU, Y. et al. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Pharmacology, v. 60, n. 10, p. 1344-1357, 2020. DOI: https://doi.org/10.1002/jcph.1713
NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington, DC: The National Academies Press, 2020.
DOI: https://doi.org/10.17226/25791
SANTORO, N. et al. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism, v. 101, n. 4, p. 1318-1343, 2016. DOI: https://doi.org/10.1210/jc.2016-1271
STANCZYK, F. Z.; MATHARU, H.; WINER, S. A. Bioidentical hormones. Climacteric, v. 24, n. 1, p. 38-45, 2021. DOI: https://doi.org/10.1080/13697137.2020.1862079
STUENKEL, C. A. Compounded bioidentical menopausal hormone therapy – a physician perspective. Climacteric, 2020. DOI: https://doi.org/10.1080/13697137.2020.1825668
STUENKEL, C. A.; MANSON, J. E. Compounded bioidentical hormone therapy: does the regulatory double standard harm women? JAMA Internal Medicine, v. 177, n. 7, p. 965-967, 2017. DOI: https://doi.org/10.1001/jamainternmed.2017.5141
STUENKEL, C. A.; MANSON, J. E. Compounded bioidentical hormone therapy: the National Academies weigh in. JAMA Internal Medicine, v. 180, n. 4, p. 547549, 2020. DOI: https://doi.org/10.1001/jamainternmed.2020.7232
License
Copyright (c) 2026 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.